Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-10-02
2011-11-29
Katakam, Sudhakar (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C562S553000, C560S046000, C514S019300, C514S171000, C514S295000, C514S299000
Reexamination Certificate
active
08067455
ABSTRACT:
The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol prodrug and crystalline forms thereof and pharmaceutical compositions thereof to treat diseases or disorders such as headache pain, post-chemotherapy or post-operative surgery nausea and vomiting, neurodegenerative disorders, and mood disorders.
REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4765539 (1988-08-01), Noakes et al.
patent: 4962885 (1990-10-01), Coffee
patent: 5112598 (1992-05-01), Biesalski
patent: 5556611 (1996-09-01), Biesalski
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5950619 (1999-09-01), van der Linden et al.
patent: 5954047 (1999-09-01), Armer et al.
patent: 5970974 (1999-10-01), van Der Linden et al.
patent: 6254853 (2001-07-01), Hendler et al.
patent: 6362234 (2002-03-01), Hendler
patent: 6451776 (2002-09-01), Stella et al.
patent: 7220875 (2007-05-01), Gallop et al.
patent: 7230003 (2007-06-01), Xu et al.
patent: 7241807 (2007-07-01), Xu et al.
patent: 7550506 (2009-06-01), Xu et al.
patent: 7576127 (2009-08-01), Xu et al.
patent: 7619110 (2009-11-01), Xu et al.
patent: 2008/0161400 (2008-07-01), Virsik et al.
patent: 2009/0005352 (2009-01-01), Xu et al.
patent: 2009/0005444 (2009-01-01), Cundy et al.
patent: 2009/0076141 (2009-03-01), Virsik
patent: 2009/0286763 (2009-11-01), Xu et al.
patent: 2009/0312424 (2009-12-01), Xu et al.
patent: WO 94/12285 (1994-06-01), None
patent: WO 94/14543 (1994-07-01), None
patent: WO 95/26234 (1995-10-01), None
patent: WO 95/26235 (1995-10-01), None
patent: WO 95/32807 (1995-12-01), None
patent: WO 99/58555 (1999-11-01), None
patent: WO 00/48572 (2000-08-01), None
patent: WO 00/54588 (2000-09-01), None
patent: WO 02/13810 (2002-02-01), None
patent: WO 2004/033424 (2004-04-01), None
patent: WO 2007/027476 (2007-03-01), None
patent: WO 2007/027477 (2007-03-01), None
patent: WO 2007/052999 (2007-05-01), None
Burton et al, Drugs Aging. 2004;21(4):229-42.
Marik, Curr Pharm Des. 2004;10(29):3639-49.
Alderman, A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms.Int. J. Pharm. Tech.&Prod. Mfr.(1984), 5(3), 1-9.
Altomare et al., Highly water-soluble derivatives of the anesthetic agent propofol: in vitro and in vivo evaluation of cyclic amino esters.Eur J Pharmaceutical Sciences(2003), 20, 17-26.
Anderson et al., α-Amino acid phenolic ester derivatives: novel water-soluble general anesthetic agents which allosterically modulate GABAAreceptors.J. Med. Chem.(2001), 44, 3582-3591.
Balimane et al., Involvement of multiple transporters in the oral absorption of nucleoside analogues.Adv Drug Deliv Rev(1999), 39, 183-209.
Bamba et al., Release mechanisms in gelforming sustained release preparations.Int. J. Pharm.(1979), 2, 307-315.
Banaszczyk et al., Propofol phosphate, a water-soluble propofol prodrug: in vivo evaluation.Anesth. Analg.(2002), 95, 1285-1292.
Beilstein Handbook of Organic Chemistry, 4th Ed., Beilstein Institute of Organic Chemistry, Frankfurt, Germany, vol. 27, part 26, 1979 (5 pages).
Borgeat et al., Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer.Can. J. Anaesth.(1994), 41(11), 1117-1119.
Borgeat et al., Propofol improves patient comfort during Cisplatin chemotherapy.Oncology(1993), 50, 456-459.
Briggs et al., An adverse reaction to the administration of disoprofol (Diprivan).Anaesthesia(1982), 37, 1099-1101.
Brooker et al., Propofol maintenance to reduce postoperative emesis in thyroidectomy patients: a group sequential comparison with isoflurane
itrous oxide.Anaesth. Intensive Care(1998), 26(6), 625-629.
Brown et al., Role of propofol in refractory status epilepticus.Ann. Pharmacother.(1998), 32, 1053-1059.
De La Cruz et al., The effect of propofol on oxidative stress in platelets from surgical patients.Anesth. Analg.(1999), 89, 1050-1055.
During et al., Controlled release of dopamine from a polymeric brain implant: in vivo characterization.Ann. Neurol.(1989), 25, 351-356.
Fieser et al., Reagents for Organic Synthesis (2004), vol. 22, Wiley Interscience (10 pages).
Gan et al., Determination of plasma concentrations of propofol associated with 50% reduction in postoperative nausea.Anesthesiology(1997), 87, 779-784.
Gennaro Ed., Remington's Pharmaceutical Sciences, Philadelphia College of Pharmacy and Science, 19th Edition (1995), Mack Publishing Company, Easton PA (5 pages).
Greene et al., Protective Groups in Organic Synthesis, 2nd ed, John Wiley & Sons, Inc., (1991) (4 pages).
Grunberg et al., Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis.Expert Opin Pharmacother(2003), 4(12), 2297-2303.
Harrison et al., Compendium of Organic Synthetic Methods, vols. 1-8, John Wiley and Sons, Inc., 1971-1995 (32 pages).
Hasan et al., Comparison of the effects of propofol and thiopental on the pattern of maximal electroshock seizures in the rat.Pharmacol Toxicol(1994), 74, 50-53.
Holtkamp et al., Propofol in subanesthetic doses terminates status epilepticus in a rodent model.Ann Neurol(2001), 49, 260-263.
Howard et al., Intracerebral drug delivery in rats with lesion-induced memory deficits.J. Neurosurg.(1989), 71, 105-112.
Krusz et al., Intravenous propofol: unique effectiveness in treating intractable migraine.Headache(2000), 40, 224-230.
Kuisma et al., Propofol in prehospital treatment of convulsive status epilepticus.Epilepsia(1995), 36(12), 1241-1243.
Langer et al. (eds.), Medical Applications of Controlled Release, vols. 1 and 2, CRC Press Inc., Boca Raton, Florida (1984) (6 pages).
Langer et al., Chemical and physical structure of polymers as carriers for controlled release of bioactive agents: a review.JMS-Rev. Macromol Chem. Phys.(1983), C23(1), 61-126.
Langley et al., Propofol. A review of its pharmacodynamic and pharmacokinetic properties and use as an intravenous anaesthetic.Drugs(1988), 35, 334-372.
Larock, Comprehensive Organic Transformations. A guide to functional group preparations (1989), VCH Publishers New York, NY (20 pages).
Lee et al., Inhibitors of acyl-CoA:cholesterolO-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: An acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.J Med Chem(1996), 39(26), 5031-5034.
Levy et al., Inhibition of calcification of bioprosthetic heart valves by local controlled-release release diphosphonate.Science(1985), 228, 190-192.
March, Advanced Organic Chemistry. Reactions, mechanisms and structure, 4th ed., Wiley Interscience, (1991) (5 pages).
Murphy et al., The antioxidant potential of propofol (2,6-diisopropylphenol).Br. J. Anaesth.(1992), 68, 613-618.
O'Neil et al. eds., The Merck Index: An encyclopedia of chemicals, drugs, and biologicals. 13th ed. (2001), pp. 156, 600, 808, 1225, and 1741-1742.
Paquette Ed., Encyclopedia of Reagents for Organic Synthesis vols. 1-8, John Wiley & Sons, New York, NY (1995) (10 pages).
Peduto et al., Biochemical and electrophysiologic evidence that propofol enhances GABAergic transmission in the rat brain.Anesthesiology(1991), 75, 1000-1009.
Phelps et al., Propofol in chemotherapy-associated nausea and vomiting.Ann. Pharmacother.(1996), 30, 290-292.
Picard et al., Prevention of pain on injection with propofol: a quantitative systematic review.Anesth. Analg.(2000), 90, 963-969.
Pop et al., Synthesis and preliminary pharmacological evaluation of some chemical delivery systems of 2,6-diisopropylphenol (propofol).Med. Chem. Res.(1992), 2, 16-21.
Raleigh et al., Pharmacokinetics of isotretinoin (iso) in rats following oral dosing or aerosol inhalation.Proc. Amer. Assoc. Cancer Research Annual Meeting(1999), 40, 397 (2 pages).
Raoof et al., In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat.Pharm. Res.(1996), 13(6), 891-895.
Sa
Dilip Usha
Gallop Mark A.
Sasikumar Vivek
Xu Feng
Dorsey & Whitney LLP
Katakam Sudhakar
XenoPort, Inc.
LandOfFree
Amino acid derived prodrugs of propofol, compositions, uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amino acid derived prodrugs of propofol, compositions, uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amino acid derived prodrugs of propofol, compositions, uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4288977